pancuronium bromide.txt CLINICAL USE Non-depolarising muscle relaxant of long duration DOSE IN NORMAL RENAL FUNCTION Initial dose: 50–100 micrograms/kgIncremental dose: 10 to 20     : micrograms/kg PHARMACOKINETICS Molecular weight                           :732.7 %Protein binding                           :80–90 %Excreted unchanged in urine     : 40–60 Volume of distribution (L/kg)       :0.15–0.38 half-life – normal/ESRD (hrs)      :2/4.3–8.2 DOSE IN RENAL IMPAIRMENT GFR (mL/MIN) 20 to 50     : Dose as in normal renal function 10 to 20     : Initial dose: 25–50 micrograms/kg Incremental dose: 5–10 micrograms/kg <10           : Initial dose: 10–25 micrograms/kg Incremental dose: 2.5–5 micrograms/kg DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES CAPD                :Unknown dialysability. Dose as in GFR <10 mL/min HD                     :Unknown dialysability. Dose as in GFR <10 mL/min HDF/high flux   :Unknown dialysability. Dose as in GFR <10 mL/min CAV/VVHD      :Unknown dialysability. Dose as in GFR 10 to 20 mL/min IMPORTANT DRUG INTERACTIONS Potentially hazardous interactions with other drugs Anaesthetics: enhanced muscle relaxant effect Anti-arrhythmics: procainamide enhances muscle relaxant effect Antibacterials: effect enhanced by aminoglycosides, clindamycin, polymyxins and piperacillinBotulinum toxin: neuromuscular block enhanced (risk of toxicity) ADMINISTRATION Reconstition– Route IV Rate of Administration Bolus Comments– OTHER INFORMATION Active metabolites accumulate in CKD 5; duration of action prolonged Tags: post-by-auto-php Continue Reading Previous Previous post: orlistat.txtNext Next post: procainamide hydrochloride.txt Related News sotalol hydrochloride.txt tazocin.txt